Introduction {#s1}
============

The transmembrane protein transporters can be divided into two groups, the solute-linked carrier (SLC) superfamily or known as influx transporters, which uptake the substrate through the cells, and the ATP-binding cassette superfamily (ABC) or efflux transporters which pump the substrates out of the cells ([@B6]). Several groups of the influx transporters uptake a variety of drugs and organic compounds from the blood into the cell, especially, the organic anion transporting polypeptides (OATPs) which are expressed in many organs such as the intestine, liver, and kidneys. OATPs have shown an important role in clinical implications for the pharmacokinetics of many drugs, including drug absorption, distribution, and elimination ([@B6]; [@B13]; [@B1]). Evidence of changes in OATP transport function has been found to affect the efficacy and safety of many drugs and leading to instability in drug disposition and response ([@B6]; [@B24]).

The genetic variations in the *SLCO1B1* gene, located on chromosome 12p12.1 and encoding the OATP1B1 influx hepatic transporter, have been widely studied in diverse populations ([@B5]; [@B16]; [@B9]; [@B15]; [@B25]; [@B24]; [@B21]; [@B17]; [@B1]). OATP1B1 is a transmembrane protein expressed on the basal side of human liver cells, which not only regulates numerous endogenous compounds, including bilirubin, estradiol, and leukotriene C4, but it also removes many drugs, such as HMG-CoA reductase inhibitors (statins), angiotensin II receptor antagonists (ARBs), angiotensin-converting enzyme inhibitors (ACEIs), rifampicin, some antidiabetic drugs, protease inhibitors (PIs), and some chemotherapies from the blood into the hepatocytes, then metabolizes and removes out of the body ([@B9]; [@B6]; [@B13]; [@B1]). The polymorphisms of the *SLCO1B1* gene not only affect the expression, localization, and function of the OATP1B1, but also the drug disposition ([@B6]; [@B24]).

Various studies have revealed the single nucleotide polymorphisms (SNPs) of the *SLCO1B1* gene reducing the functional transport activity of OATP1B1 and causing some adverse drug reactions (ADRs) ([@B16]; [@B15]; [@B6]; [@B24]; [@B13]; [@B1]). *SLCO1B1* variants, including *SLCO1B1\*1a*, *SLCO1B1\*1b* (c.388A\>G, N130D), *SLCO1B1\*5* (c.521T\>C, V174A), and *SLCO1B1\*15* (c.388A\>G and c.521T\>C) have been reported in affecting the transport activity and drug disposition ([@B10]; [@B8]; [@B6]; [@B21]; [@B18]). Statin-taking patients with *SLCO1B1* polymorphisms showed the area under the plasma-time curve (AUC) up to 130% higher than the patients without the *SLCO1B1* polymorphisms ([@B5]; [@B25]). Also, a reduced transporter activity caused more susceptible to statin-induced myotoxicity in the group of patients carrying *SLCO1B1* polymorphisms than those without polymorphisms ([@B22]; [@B7]; [@B21]). *SLCO1B1\*5* has been strongly associated with myopathy among the simvastatin users with an odds ratio (OR) ranging from 4.5 in heterozygotes to 16.9 in homozygotes ([@B12]; [@B5]; [@B14]; [@B25]; [@B9]; [@B20]; [@B23]; [@B6]; [@B3]; [@B4]; [@B2]; [@B13]). Also, *SLCO1B1\*15* showed over 70% reduction in the transport activity compared with wild type and showed the association with myopathy in patients taking pravastatin and atorvastatin ([@B5]; [@B25]; [@B6]; [@B24]; [@B13]).

Currently, there is a lack of studies reporting the frequency of the SNPs of *SLCO1B1* in the Thai population. The translational decision in the clinical practices has always used the data from the reports in other populations, the Han Chinese population, for instance. The objective of this study was to investigate the regional frequencies of the two functional SNPs of *SLCO1B1* in the Thai population. The findings of this study will serve as the Thai pharmacogenetic data source for decision in drug therapy in a specific group of patients, especially, in patients who will be treated with statins or other medications that are affected by these genetic variants.

Materials and Methods {#s2}
=====================

Samples {#s2_1}
-------

In the present study, we enrolled 1,205 samples from the previous cohort of [@B26], which were collected from August 2008 to March 2009 by the Health System Research Institute. The selected samples were then categorized into five regions of Thailand, including Northern, Northeastern, Central, Southern, and Bangkok.

Genotyping Analysis {#s2_2}
-------------------

Genotyping of *SLCO1B1* polymorphisms was performed using allele-specific TaqMan^®^ MGB probe 5\' nuclease assay with real-time polymerase chain reaction (PCR) ViiA7™ system (Applied Biosystems, Life Technologies). The allele-specific TaqMan^®^ MGB probe 5\' nuclease chain reaction assay was performed with primers of *SLCO1B1* c.388A\>G (rs2306283; on reference sequence NM_006446.4, assay ID: C:\_1901697_20) and c.521T\>C (rs4149056; on reference sequence NM_006446.4, assay ID: C:30633906_10). Each 6 μl of PCR mixture contained 2 μl of genomic DNA in a concentration of 5 ng/μl, 2.5 μl of TaqMan^®^ Genotyping Mastermix, 0.25 μl of allele-specific TaqMan^®^ MGB probe and sequence-specific primer kit, and 1.25 μl of DNase-free water. The thermal cycler program started with 10 min at 95°C, followed by 50 cycles of 15 s at 92°C and 90 s at 60°C. The allelic discrimination plot was analyzed by ViiA7™ software (Applied Biosystems, Life Technologies). Allele 1 was labeled with VIC^®^ dye fluorescence, and allele 2 was labeled with FAM™ dye fluorescence.

OATP1B1 Phenotypes Based on *SLCO1B1* Genotypes {#s2_3}
-----------------------------------------------

The Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for *SLCO1B1* and simvastatin-induced myopathy 2014 update was used to assign the likely OATP1B1 phenotype (normal function, intermediate function, and low function) and \* allele nomenclature ([@B21]).

Statistical Analysis {#s2_4}
--------------------

The frequencies of two SNPs of *SLCO1B1*, c.388A\>G and c.521T\>C, were checked for Hardy-Weinberg equilibrium using the R statistic version 3.6.1, the R Foundation for Statistical Computing. Fisher\'s Exact and Chi-square tests were used to determine the statistical difference between the minor alleles and haplotype frequencies between the geographical regions of Thailand using SPSS version 18.0 for Window, SPSS Inc., Chicago, IL, United States. A *p*-value of less than 0.05 was considered significant.

Results {#s3}
=======

Allele and Haplotype Frequencies of *SLCO1B1* in Thai Population {#s3_1}
----------------------------------------------------------------

The allele frequencies of the non-synonymous polymorphic variants in the coding region c.388A\>G (N130D) and c.521T\>C (V174A) of *SLCO1B1* gene and haplotype frequencies of *SLCO1B1\*1a*, *\*1b*, *\*5*, and *\*15* in 1,205 healthy Thai samples distributed over five regions of Thailand are shown in [**Table 1**](#T1){ref-type="table"}. All detected variations were in Hardy-Weinberg equilibrium (*p*\>0.05). The allele frequencies of c.388A\>G were similar among five regions. At the same time, the SNP c.521T\>C showed the most frequency in Bangkok and the least in the Southern region, however, there were no significant differences in minor allele frequencies of these two SNPs among the five regions of Thailand. The most frequent haplotype was *SLCO1B1\*1b* (frequency: 0.654), followed by *\*1a* (frequency: 0.217), *\*15* (frequency: 0.128), and *\*5* (frequency: 0.001). We did not observe significant differences in haplotype frequencies among the five regions ([**Table 1**](#T1){ref-type="table"}).

###### 

The minor allele frequencies of *SLCO1B1* c.388A\>G (rs2306283) and c.521T\>C (rs4149056) and the observed frequencies for selected *SLCO1B1* haplotypes in Thais distributed among the five regions of Thailand.

  SLCO1B1                         Total       Northern   Central   Northeastern   Southern   Bangkok   *p*-value
  ------------------------------- ----------- ---------- --------- -------------- ---------- --------- -----------
  **Minor allele frequencies**                                                                         
  **N**                           **1,205**   **279**    **318**   **379**        **159**    **70**    
  c.388A\>G                       0.782       0.805      0.769     0.792          0.755      0.757     0.328
  c.521T\>C                       0.129       0.120      0.143     0.137          0.085      0.150     0.090
  **Haplotype frequencies (%)**                                                                        
  **N**                           **2,410**   **558**    **636**   **758**        **318**    **140**   
  *\*1a* ^a^                      21.74       19.53      22.96     20.84          24.21      24.29     0.382
  *\*1b* ^b^                      65.39       68.46      62.74     65.44          67.30      60.71     0.187
  *\*5* ^c^                       0.08        0.00       0.16      0.00           0.31       0.00      0.450
  *\*15* ^d^                      12.78       12.01      14.15     13.72          8.18       15.00     0.071

**^a^**, \*1a = wild type at all loci; **^b^**, \*1b =rs2306283 G allele (A ancestral) (c.388A\>G, p.N130D); **^c^**, \*5 = rs4149056 Callele (T ancestral) (c.521T\>C, p.V174A); ^d^, \*15 = rs2306283 G allele (A ancestral) and rs4149056 C allele (T ancestral).

The Phenotypes of OATP1B1 Transporter Based on *SLCO1B1* Diplotypes in Thai Population {#s3_2}
--------------------------------------------------------------------------------------

The phenotypes of the OATP1B1 transporter have been assigned based on the diplotype at c.388A\>G and c.521T\>C of the *SLCO1B1* gene. The phenotype frequencies distributed over the five regions of Thailand and worldwide are shown in [**Table 2**](#T2){ref-type="table"}.

###### 

OATP1B1 phenotypes based on *SLCO1B1* diplotypes in Thais distributed among the five regions of Thailand.

  --------------------------------------------------------------------------------------------------------------------------
  OATP1B1 phenotypes      *SLCO1B1* diplotypes   Phenotype frequencies (%)                                           
  ----------------------- ---------------------- --------------------------- ------- ------- ------- ------- ------- -------
  Normal function         *\*1a/\*1a*\           55 -- 88                    75.85   76.70   73.27   74.14   84.91   72.86
                          *\*1a/\*1b*\                                                                               
                          *\*1b/\*1b*                                                                                

  Intermediate function   *\*1a/\*5*\            11 -- 36                    22.57   22.58   24.84   24.27   13.21   24.29
                          *\*1a/\*15*\                                                                               
                          *\*1b/\*5*\                                                                                
                          *\*1b/\*15*                                                                                

  Low function            *\*5/\*5*\             0 -- 6                      1.58    0.72    1.89    1.58    1.89    2.86
                          *\*5/\*15*\                                                                                
                          *\*15/\*15*                                                                                
  --------------------------------------------------------------------------------------------------------------------------

**^a^**, Frequency of the polymorphism varies by ancestral group.

Discussion {#s4}
==========

Numerous data have reported the genetic variations of the *SLCO1B1* gene for the determination of clinical drug response. The allele frequencies of the polymorphic variations and haplotype frequencies of the *SLCO1B1* gene, which are *SLCO1B1\*1a*, *SLCO1B1\*1b*, *SLCO1B1\*5*, and *SLCO1B1\*15,* have been studied in the various population groups. Among the published reports, *SLCO1B1* c.388A\>G (N130D) and *SLCO1B1* c.521T\>C (V174A) are the most commonly investigated SNPs in the various ethnic groups. This present study investigated the frequencies of these two common polymorphic variations in the Thai population distributed across five regions of Thailand. We found that allele frequencies of the c.388A\>G and c.521T\>C variants were close to the frequencies reported in other Asian populations, including Han Chinese, Japanese, Korean, and Vietnamese ([@B11]; [@B18]). When compared separately, the frequencies of c.388A\>G were similar in Asian ancestry but showed differently in Asian Indians and Caucasians, while the frequencies of c.521T\>C showed similarity in all ethnicity except Asian Indian and African ancestry ([**Table 3**](#T3){ref-type="table"} and [**Figure 1**](#f1){ref-type="fig"}).

###### 

The observed frequencies for selected *SLCO1B1* haplotypes in the Thai population and other geographical groups.

  *SLCO1B1* haplotypes   Haplotype frequencies (%)                                 
  ---------------------- --------------------------- ---- ---- ---- ---- ---- ---- ----
  *\*1a*                 22                          27   47   49   34   50   37   17
  *\*1b*                 65                          60   46   31   66   22   39   78
  *\*5*                  0                           0    0    5    0    1    0    0
  *\*15*                 13                          13   6    15   0    14   24   3

**^a^**, Asian = East Asian, Chinese, Japanese, Korean, Malays, and Vietnamese; **^b^**, SW Asian = South/Central Asian and Indian; **^c^**, Caucasian = American, European, Canadian, German, Finnish, French, Dutch, and Turkish; **^d^**, African = American, North African, Sub-Saharan Africa, Ugandan, and Tanzanian.

![The observed frequencies for selected *SLCO1B1* haplotypes in the Thai population and other geographical groups (data adapted from [@B21]).](fphar-11-00728-g001){#f1}

The most remarkable haplotypes of the *SLCO1B1* gene, *SLCO1B1\*5* and *SLCO1B1\*15*, have been reported to reduce the number and function of the OATP1B1 transporter. These haplotypes not only alter the disposition of many therapeutic drugs, including various statins, but also affect the adverse events, especially statin-induced myotoxicity (0.3% in Thai population). Many reports have confirmed that the *SLCO1B1\*5* allele is associated with statin-induced myotoxicity in several populations ([@B7]; [@B22]; [@B21]). Nevertheless, the frequency of *SLCO1B1\*5* haplotype in Asian population was very low when compared with other geographical groups ([**Figure 1**](#f1){ref-type="fig"}). Published research on haplotype frequencies of the *SLCO1B1\*5* have shown the prevalence of 1.2% in a Chinese population, 0.7% in Japanese, and absent in Korean, and Vietnamese. We observed the *SLCO1B1\*5* haplotype having a frequency of 0.08% in the Thai population. *SLCO1B1\*1b* is the most abundant haplotype in Asian populations (approximately 55% to 70%). The frequency of *SLCO1B1\*15* in our study showed a similar range compared to the Asian populations but lower when compared with South American populations ([@B19]; [@B11]).

We observed similar diplotype frequencies of the OATP1B1 transporter in the Thai population compared to previous reports in Asian populations, including Han Chinese, Japanese, Korean, and Vietnamese ([@B19]; [@B11]). The *SLCO1B1* phenotypes based on diplotypes in the Thai population were in agreement with the comprehensive data of the function of the OATP1B1 transporter ([**Table 3**](#T3){ref-type="table"}).

In conclusion, frequencies of the *SLCO1B1* variants and the subsequent OATP1B1 activity in a large cohort of Thais can provide important information for the guidance of personalized drug therapy.
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